National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Illinois

Other

Vanderbilt University

Vadim Gaponenko

Nadya Tarasova

Steven Jules Ackerman

Sergey G Tarasov

Fan Gao Laffey

Ben Hitchinson

Boris Garnier

Hazem Abdelkarim

Michael C Dean

Christopher J Michejda

Alan O Perantoni

Olga Timofeeva

Joseph Kates

Alla Ivanova

A C&#x2014;C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

Peptide inhibition of CCR3-mediated diseases or conditions

A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.

Peptide-based stat inhibitor

The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal &#x3b1;-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.

Lipopeptide inhibitors of RAS oncoproteins

Growing community of inventors

Naperville, IL, United States of America

Vadim Gaponenko